title: Randomized study of early intravenous esmolol versus oral beta-blockers in preventing post-CABG atrial fibrillation in high risk patients identified by signal-averaged ECG: results of a pilot study.
abstract: BACKGROUND
  Patients with prolonged signal-averaged ECG have four times higher risk for development of atrial fibrillation (AF) after coronary artery bypass surgery (CABG). Incidence of AF is reduced, but not eliminated by prophylaxis with beta-blockers. The limitations of prophylaxis with oral beta-blockers may be related to the delayed effect of oral therapy. We performed a pilot study of the efficacy of early intravenous esmolol and an oral beta-blocker regimen for prevention of postoperative AF.
  
  
  METHODS
  Fifty patients referred for CABG and considered to be at high risk for postoperative AF on the basis of prolonged signal-averaged ECG P wave duration > 140 ms were randomized to receive either a 24-hour infusion of esmolol 6-18 hours after CABG, at an average dose 67 +/- 7 microg/kg/min, followed by oral beta-blockers versus oral beta-blockers only beginning on postoperative day 1.
  
  
  RESULTS
  Seven of 27 patients (26%) in the esmolol group and 6 of 23 patients (26%) in the oral beta-blocker group developed postoperative AF, P = NS. The mean time of onset of AF (2.7 +/- 0.5 vs 2.7 +/- 0.3 postoperative day, P = NS) and the median duration of AF (10 [2192] vs 7 [1.16] hours, P = NS) were similar between the two groups. Eleven (41%) patients treated with esmolol developed adverse events (hypotension: 8, bradycardia requiring temporary pacing: 2, left ventricular failure:1 patient) as compared to only one patient (4%) in the beta-blocker group who developed hypotension, P = 0.006.
  
  
  CONCLUSIONS
  This randomized controlled pilot study suggests that intravenous esmolol is less well tolerated and offers no advantages to standard beta-blocker in preventing AF after CABG.
authors.affiliation: Division of Cardiology, St. Luke's-Roosevelt Hospital Center, 1111 Amsterdam Ave, New York, NY 10025. JSS7@columbia.edu
authors.forename: Nomeda
authors.initials: N
authors.lastname: Balcetyte-Harris
authors.forename: Jacqueline E
authors.initials: JE
authors.lastname: Tamis
authors.forename: Peter
authors.initials: P
authors.lastname: Homel
authors.forename: Edith
authors.initials: E
authors.lastname: Menchavez
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Steinberg
mesh_terms: D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000368:Aged; D001281:Atrial Fibrillation / Q000517:prevention & control*; D001919:Bradycardia / Q000139:chemically induced; D001026:Coronary Artery Bypass; D004334:Drug Administration Schedule; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011183:Postoperative Complications / Q000517:prevention & control*; D011412:Propanolamines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C036604:esmolol